相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling
Size Li et al.
ARCHIVES OF TOXICOLOGY (2021)
Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
Hongrui Liu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling
Mariana Guimaraes et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Pharmacokinetics in children with chronic kidney disease
Anne M. Schijvens et al.
PEDIATRIC NEPHROLOGY (2020)
Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis
Changcheng Shi et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling
Yong Chen et al.
AAPS PHARMSCITECH (2020)
Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis
Addisu Melese et al.
BMC INFECTIOUS DISEASES (2020)
Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy
Feifan Xie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation
Xiao-Chen Wei et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment
Xiang You et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper
J. Turnidge et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis
Tomoyuki Yamada et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2020)
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment
Lingling Ye et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
Aref Shariati et al.
SCIENTIFIC REPORTS (2020)
Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment
Nicolas Gregoire et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients
Toshiharu Urakami et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics
Min Zhang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Daptomycin
Mohsen Heidary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Population pharmacokinetics of daptomycin in critically ill patients
A. Soraluce et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Safety of high-dose daptomycin in patients with severe renal impairment
Chih-Hsun Tai et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections
Massimo Sartelli et al.
WORLD JOURNAL OF EMERGENCY SURGERY (2018)
Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women
Andre Dallmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations
Chie Emoto et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
Xiaoying Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
Kimberly C. Claeys et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
W. Zhou et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach
Trevor N. Johnson et al.
DRUG METABOLISM AND DISPOSITION (2016)
2015 ESC Guidelines for the management of infective endocarditis
Gilbert Habib et al.
EUROPEAN HEART JOURNAL (2015)
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
Tao Zhang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Daptomycin in paediatrics: current knowledge and the need for future research
Nicola Principi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Daptomycin use in pediatric patients
Cheryl Durand et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2014)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
Dennis L. Stevens et al.
CLINICAL INFECTIOUS DISEASES (2014)
Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections A Systematic Review and Meta-analysis
Andre C. Kalil et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment
Ricardo L. Chaves et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3-24 Months of Age
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Efficacy and Safety of Daptomycin in Patients with Renal Impairment: A Multicenter Retrospective Analysis
Ravina Kullar et al.
PHARMACOTHERAPY (2014)
Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?
Marco Falcone et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
Kaori Yabuno et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis
S. J. van Hal et al.
CLINICAL INFECTIOUS DISEASES (2012)
Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials
R. Leong et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants
Michael Cohen-Wolkowiez et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Case Report of a Successful Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and MRSA/Vancomycin-Resistant Enterococcus faecium Cholecystitis by Daptomycin
Carlo Tascini et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis
Sujata M. Bhavnani et al.
CLINICAL INFECTIOUS DISEASES (2010)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
Abhijit Chakraborty et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Emerging evidence of the impact of kidney disease on drug metabolism and transport
T. D. Nolin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections
Susan M. Abdel-Rahman et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2008)
Daptomycin does not exert immunomodulatory effects in an experimental endotoxin model of human whole blood
Christiane Thallinger et al.
PHARMACOLOGY (2008)
Relationship between serum albumin level and aging in community-dwelling self-supported elderly population
Ikuko Gomi et al.
JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY (2007)
Daptomycin - A review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia
Philip I. Hair et al.
DRUGS (2007)
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
Mark Benvenuto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones et al.
CLINICAL PHARMACOKINETICS (2006)
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
BH Dvorchik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
分享论文
